Cancer Trials Support Unit

Thermo Fisher Scientific’s PPD Clinical Research Business Selected to Support National Cancer Institute’s Cancer Trials Support Unit

Retrieved on: 
Thursday, September 15, 2022
Oncology, Health, Clinical Trials, General Health, Research, Science, National, World, Digital, Health, Fisher Scientific, Time, Laboratory, Department, Guest appearance, DHHS, World Health Organization, Shadow King, Mindful Scientific Inc., National Institutes of Health, Pharmaceutical Services Negotiating Committee, Decentralization, Industry, Applied Biosystems, Invitrogen, Thermo Fisher Scientific, Patient, Cancer, NCI, CTSU, Solution, PPD, Patheon, Documentation, Science, Drug development, Collection, Method, Death, Research, United States Department of Health and Human Services, IDIQ, MCO, National Cancer Institute, NIH, Contract research organization, Cancer Trials Support Unit, Pharmaceutical industry

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded a 10-year Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract by the National Cancer Institute (NCI), part of the National Institutes of Health, to support NCIs Cancer Trials Support Unit (CTSU).

Key Points: 
  • The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been awarded a 10-year Indefinite-Delivery, Indefinite-Quantity (IDIQ) contract by the National Cancer Institute (NCI), part of the National Institutes of Health, to support NCIs Cancer Trials Support Unit (CTSU).
  • Thermo Fishers PPD clinical research business has three decades of experience successfully delivering clinical research services to governmental agencies, contractors and nonprofits in conducting therapeutic, vaccine and medical device studies on a global scale across all trial phases and a broad array of therapeutic areas.
  • NCIs focus on progressing cancer research across the nation is one we all support, to advance scientific knowledge and to help all people live longer, healthier lives, said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific.
  • The research that NCI champions is vital to improving the outcomes of patients battling this group of diseases.

Westat to Continue Support of NCI's Cancer Trials Support Unit (CTSU)

Retrieved on: 
Tuesday, August 30, 2022
National, Cancer Trials Support Unit, National Cancer Institute, Electronic health record, Research, Experiment, IDIQ, Informatics, United States Department of Health and Human Services, Children and Family Court Advisory and Support Service, Department, NIH, Information technology, Education, CTSU, Patient-Reported Outcomes Measurement Information System, Patient, NCI, Practice, Health, CORE, Transport, HHS, Efficiency, Pharmaceutical industry, Medicine, Westat

ROCKVILLE, Md., Aug. 30, 2022 /PRNewswire-PRWeb/ -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded the Cancer Trials Support Unit (CTSU) IDIQ contract 75N91022D00009 to Westat for a 10-year ordering period (if all options are exercised). This project has been funded in whole or in part with federal funds from the NCI, NIH, Department of Health and Human Services (HHS).

Key Points: 
  • Westat will partner with NCI, providing quality service and value through finding efficiencies, stakeholder collaboration, and innovative solutions to support the transformation of the clinical trials enterprise.
  • ROCKVILLE, Md., Aug. 30, 2022 /PRNewswire-PRWeb/ -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded the Cancer Trials Support Unit (CTSU) IDIQ contract 75N91022D00009 to Westat for a 10-year ordering period (if all options are exercised).
  • Our Westat team looks forward to working with the NCI cancer research program to carry out and grow its mission," notes Nancy Dianis, R.N., M.S.
  • Westat provides innovative professional services support to clients in addressing challenges to improve outcomes in health, education, social policy, and transportation.

Hawaii Cancer Care Deploys Deep Lens’ AI-Screening Tool VIPER™ to Expand Clinical Trial Offering to Patients

Retrieved on: 
Tuesday, April 6, 2021
Technology, Hospitals, Clinical trials, Software, Networks, Other Health, Biotechnology, Health, Data management, Oncology, Health sciences, Health, Clinical pharmacology, Pharmaceutical industry, Clinical research, Clinical trial, Design of experiments, Cancer, Cancer Trials Support Unit, Cancer prevention, Hawaii Cancer Care, Deep Lens

Hawaii Cancer Care and Deep Lens today announced a partnership that will expand the clinical trial offering for patients in Hawaii through the integration of artificial intelligence-based clinical trial screening and enrollment platform, VIPER.

Key Points: 
  • Hawaii Cancer Care and Deep Lens today announced a partnership that will expand the clinical trial offering for patients in Hawaii through the integration of artificial intelligence-based clinical trial screening and enrollment platform, VIPER.
  • Through the integration of VIPER, Hawaii Cancer Care will be able to quickly and more effectively identify, triage and match patients to precision-based oncology clinical trials.
  • Like Hawaii Cancer Care, any practice that utilizes OncoEMR can easily integrate VIPER and all other Deep Lens screening services free of charge.
  • Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

Florida Cancer Specialists & Research Institute Streamlines Sharing of Images and Information Among Multiple Providers to Enhance Patient Care

Retrieved on: 
Friday, March 12, 2021
American Society of Clinical Oncology, Health care, Medical specialties, Medicine, Health informatics, Cancer Trials Support Unit

When all providers are able to view and exchange patient information in real time, it aids timely clinical decision making and enhances the patient experience.

Key Points: 
  • When all providers are able to view and exchange patient information in real time, it aids timely clinical decision making and enhances the patient experience.
  • Florida Cancer Specialists radiology team and leadership continue to share an unwavering commitment to patient care and innovation, said Ben Brown, president of Thinking Systems.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • Founded in 1996, Thinking Systems continues to deliver on our mission to enhance patient care by delivering innovative imaging informatics technologies.

Solano Hematology Oncology Adopts Deep Lens’ VIPER™ to Improve Patient Access to Clinical Trials

Retrieved on: 
Wednesday, February 24, 2021
Software, Research, Pharmaceutical, Oncology, Data management, Technology, Hospitals, Clinical trials, Science, Biotechnology, Practice Management, Health, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Oncology, Patient participation, Texas Oncology, Cancer Trials Support Unit, Solano Hematology Oncology, Deep Lens

Solano Hematology Oncology and Deep Lens today announced a strategic collaboration designed to more effectively identify, screen and match patients to precision-based clinical oncology trials using VIPER, Deep Lens artificial intelligence-based screening and enrollment platform.

Key Points: 
  • Solano Hematology Oncology and Deep Lens today announced a strategic collaboration designed to more effectively identify, screen and match patients to precision-based clinical oncology trials using VIPER, Deep Lens artificial intelligence-based screening and enrollment platform.
  • VIPER will be utilized by oncology care teams at Solano Hematology Oncology in Vallejo and the Cancer Treatment Center of Vacaville.
  • It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, patient participation in these trials is often as low as three percent.
  • Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

Genomic Testing Cooperative Establishes a Program to Address Cancer Disparity by Offering Molecular Profiling to Minority Patients without Adequate Insurance Coverage and Facilitating Access to Precision Medicine and Enrollment in Clinical Trials

Retrieved on: 
Tuesday, February 2, 2021
Research, General Health, Gay & Lesbian, Professional services, Oncology, African-American, Consumer, Genetics, Clinical trials, Science, Insurance, Health, Health sciences, Health, Clinical pharmacology, Clinical research, Drug discovery, Pharmaceutical industry, Clinical trial, Design of experiments, Precision medicine, Cancer Trials Support Unit, COVID-19 drug development

One of the reasons for this disparity is poor access to precision medicine and exclusion from clinical trials or studies evaluating the potential differences in the biology of their cancer.

Key Points: 
  • One of the reasons for this disparity is poor access to precision medicine and exclusion from clinical trials or studies evaluating the potential differences in the biology of their cancer.
  • The molecular profiling report provides information regarding potential clinical trials that will help the patients evaluate their options to participate and be treated in these clinical trials.
  • Participation in this program will increase access of underserved patients and reduce disparity within community-based cancer care.
  • Minority patients are not adequately represented in the process for developing innovative medicine nor in the implementation of state-of-the-art medicine.

Broome Oncology Selects Deep Lens’ VIPER™ to Provide Community Cancer Patients With Better, Faster Access to Cancer Trials

Retrieved on: 
Monday, January 11, 2021
Software, Research, Pharmaceutical, Oncology, Data management, Technology, Genetics, Clinical trials, Science, Biotechnology, Practice Management, Health, Health sciences, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Cancer Trials Support Unit, Broome Oncology LLC, Deep Lens

With the upcoming integration of VIPER to Broome Oncology, clinical trial care team members will improve the identification, screening, and matching of patients to precision-based clinical oncology trials in real-time.

Key Points: 
  • With the upcoming integration of VIPER to Broome Oncology, clinical trial care team members will improve the identification, screening, and matching of patients to precision-based clinical oncology trials in real-time.
  • By partnering with Deep Lens we can better provide our patients access to cutting-edge treatments in clinical trials, said Ronald P. Harris, DO, Medical Director of Research at Broome Oncology.
  • The VIPER platform will help in trial pre-screening by identifying and matching cancer patients to eligible trials through AI, streamlining this complicated process for our staff.
  • Deep Lens is a software company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

Massive Bio Has Been Awarded a Contract by the NCI to Develop an Oncology Based Artificial Intelligence-Enabled Clinical Trial Recruitment Tool

Retrieved on: 
Thursday, December 17, 2020
Biotechnology, General Health, Health, Oncology, Clinical research, Health sciences, Medical research, Health, Clinical trials, Pharmaceutical industry, Clinical pharmacology, Design of experiments, Patient recruitment, Cancer Trials Support Unit

The development of the DLCTMS has the potential to enhance clinical trial enrollment and retention across NCI clinical trial networks and beyond.

Key Points: 
  • The development of the DLCTMS has the potential to enhance clinical trial enrollment and retention across NCI clinical trial networks and beyond.
  • Massive Bio has focused on improving patient enrollment for clinical trials since the company was founded in 2015.
  • Massive Bio controls patient enrollment value chain starting patient identification, following with AI based virtual pre-screening outside the site and resolving last mile issues for clinical trial enrollment.
  • While improving cancer patients lives, Massive Bio serves close to two dozen pharmaceutical companies, contract research organizations (CROs) and providers.

TRACON Announces Publication in Cancer Cell of Clinical Data that Provides Molecular Insight into the Mechanism of Action of TRC102 and Patient Populations Most Likely to Respond to Treatment

Retrieved on: 
Monday, November 23, 2020
Cancer, Oncology, Health, Causes of death, Brain tumor, Glioblastoma, Cancer Trials Support Unit

Following treatment, the patient was considered an exceptional responder through the achievement of a near compete response lasting 45 months at the most recent follow-up.

Key Points: 
  • Following treatment, the patient was considered an exceptional responder through the achievement of a near compete response lasting 45 months at the most recent follow-up.
  • The publication authors hypothesized that the combination of Temodar and TRC102 was effective because all necessary DNA repair pathways were compromised genetically or through the activity of TRC102.
  • TRC102 is being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the NCI through a Cooperative Research and Development Agreement.
  • The NCI data are also consistent with the results from the Phase 2 trial of Temodar and TRC102 in refractory glioblastoma.

BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1

Retrieved on: 
Wednesday, June 10, 2020
Oncology, Health, Chemicals, Plastics, Manufacturing, Clinical trials, Pharmaceutical, Biotechnology, RTT, Medicine, Clinical medicine, Cancer, Acute lymphocytic leukemia, 75th United States Congress, National Cancer Institute, Leukemia, Acute lymphoblastic leukemia, Bryostatin, Moxetumomab pasudotox, Cancer Trials Support Unit, AMRI, BryoLogyx

Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

Key Points: 
  • Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
  • These two agreements with Neurotrope will accelerate our drive to clinical trials to demonstrate proof-of-concept in patients.
  • The agreements should position BryoLogyx to begin clinical trials with the NCI in late 2020.
  • Under the first agreement, Neurotrope will transfer to BryoLogyx the right to develop bryostatin1 for the potential treatment of CD22+ B-cell acute lymphoblastic leukemia (ALL).